Circuit Clinical Welcomes Business Development Expert Michael Schooley to Team
Michael Schooley joins Circuit Clinical from a distinguished 18-year career at LabCorp where he was VP of Business Development. During his tenure at LabCorp he held several roles of increasing responsibility, most recently he led business development in the physician and health systems segments as well as leading the Federally Qualified Health Centers (FQHC) sales team across the Northeast US. Mr. Schooley has over 25 years of healthcare related business development experience with proficiency in building high performing clinical sales teams. Mr. Schooley will lead the business development efforts, including digital, clinical trials, and biospecimen business lines.
“Adding Mike Schooley’s expertise in business development and building highly proficient sales teams greatly advances Circuit Clinical's goals of growth across our business lines,” said CEO of Dr. Irfan Khan. "Mike’s 18 years of experience at LabCorp with Federally Qualified Health Centers will help us deliver clinical trials as a care option to a diverse population of new patients. Mike is the right leader to help Circuit accomplish those goals.”
About Circuit Clinical Solutions
Circuit Clinical, one of the largest integrated research organizations in the USA, is dedicated to empowering patients choosing clinical research as a care option. Born from the experiences of a physician conducting clinical research in his private practice, Circuit Clinical is committed to transforming physician and participant engagement by delivering turnkey clinical research services and an award-winning patient platform.
TrialScout technology empowers patients seeking, considering, and participating in clinical research while delivering deep patient engagement informatics. TrialScout ratings and reviews give research participants an ongoing voice throughout their journeys. Built by experts in healthcare, clinical research, and online patient engagement, TrialScout is the innovation that clinical research participants and the industry alike have been waiting for.